MedTrace Logo

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

NCT03960268 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-06-04

No results posted yet for this study

Summary

Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

Conditions

Interventions

DRUG

Brodalumab

interleukin 17 receptor A antagonist

Sponsors & Collaborators

  • Valeant Pharmaceuticals

    collaborator INDUSTRY

  • Rockefeller University

    lead OTHER

Principal Investigators

  • John W Frew, MD · Rockefeller University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-28
Primary Completion
2020-06-01
Completion
2020-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03960268 on ClinicalTrials.gov